Essentially, cereblon and its target proteins can change shape to form a complex with the cereblon, the target, and the ...

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, has made significant advancements in drug discovery as highlighted in a cover article published in Science. The research ...

Monte Rosa’s AI/ML-powered insights dramatically increase targetable protein space for molecular glue degraders, unlocking ...

Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) rallied 49% Monday morning after the biotech signed an exclusive license deal with Novartis (NYSE:NVS) to advance its VAV1-directed molecular glue ...

Monte Rosa Therapeutics signed a development and commercialization deal with Novartis that could pay the biotech up to $2.1 billion. The agreement is for Monte Rosa's MRT-6160 drug and other ...

Monte Rosa Therapeutics, Inc. secured a $150 million upfront partnership with Novartis to develop MRT-6160 for immune-mediated conditions, with a potential $2.1 billion in milestone payments.

Explore Monte Rosa Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for GLUE.

Shares of Monte Rosa Therapeutics (GLUE) have gained 22.5% over the past four weeks to close the last trading session at $5.01, but there could still be a solid upside left in the stock if short-term ...

In June 2024, Monte Rosa Therapeutics had US$262m in cash, and was debt-free. Looking at the last year, the company burnt through US$68m. That means it had a cash runway of about 3.9 years as of ...

Monte Rosa will also be eligible for future payments of up to $2.1 billion as well as royalties on net sales outside the U.S. Shares of Monte Rosa surged 32% to $6.46 in premarket trade following ...

Monte Rosa’s AI/ML-powered insights dramatically increase targetable protein space for molecular glue degraders, unlocking new opportunities to address previously undruggable therapeutic targets ...

BOSTON, July 03, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ...